Stanford, California 94305

  • Myeloproliferative Disorders (MPD)


To improve survival outcomes for patients with MDS and MPD with a nonmyeloablative allogeneic hematopoietic cell transplant.

Study summary:

Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)


Inclusion Criteria:- Myelodysplastic Syndromes - Myeloproliferative Disorders - HLA matched donor available Exclusion Criteria:- organ dysfunction - HIV positive



Primary Contact:

Principal Investigator
Ginna Laport
Stanford University

Backup Contact:


Location Contact:

Stanford, California 94305
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.